-
90073ARP (N-(Aminooxyacetyl)-N&rsquo-(D-biotinoyl)hydrazine, trifluoroacetic acid salt) reacts with the exposed aldehyde group formed at abasic sites in damaged DNA, allowing the DNA to be labeled with biotin groups (1,2). The labeled DNA can then be
-
1042500-200MGThis product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the
-
11009-100G-FBiochem/physiol Actions Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
-
11009-25G-FBiochem/physiol Actions Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
-
11009-500G-FBiochem/physiol Actions Substrate of nitric oxide synthase, which is converted to citrulline and nitric oxide (NO). Induces insulin release by a nitric oxide-dependent mechanism.
-
A4474-100GOur SAFC ® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity
-
A4474-10KGOur SAFC ® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity
-
A4474-1KGOur SAFC ® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity
-
A4474-25KGOur SAFC ® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity
-
A5006-100GApplication L-arginine has been used to study non-enzymatic gluconeogenesis. It has also been used to study the effects of L-arginine supplementation on kidney and liver injury in rats with myocardial infarction.
-
A5006-1KGApplication L-arginine has been used to study non-enzymatic gluconeogenesis. It has also been used to study the effects of L-arginine supplementation on kidney and liver injury in rats with myocardial infarction.
-
A5006-500GApplication L-arginine has been used to study non-enzymatic gluconeogenesis. It has also been used to study the effects of L-arginine supplementation on kidney and liver injury in rats with myocardial infarction.